Janssen Pharmaceuticals, Inc.

Ewa Wajs

Wayne C Drevets

Jaskaran Singh

David Wood Hough

Honglan Li

The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

Growing community of inventors

Beerse, Belgium

Ewa Wajs